<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Heart Failure Management | Cardiovascular Pharmacology</title>
    
    <!-- Preconnect for performance -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- Main Stylesheet -->
    <link rel="stylesheet" href="../styles/main.css">
    
    <!-- MathJax Configuration -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true
        },
        svg: { fontCache: 'global' }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <!-- Skip Link -->
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <!-- Reading Progress Bar -->
    <div class="reading-progress-container" aria-hidden="true">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Theme Toggle -->
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="page-wrapper">
        <!-- Floating Mini-TOC -->
        <aside class="floating-toc" id="floating-toc" aria-label="On this page">
            <div class="floating-toc-header">
                <span class="floating-toc-icon">üìë</span>
                <span>On this page</span>
            </div>
            <nav class="floating-toc-nav">
                <ul class="floating-toc-list">
                    <!-- Populated by JS -->
                </ul>
            </nav>
        </aside>

        <div class="container">
            <article class="document-article" role="main" id="main-content">
                <!-- Top Navigation -->
                <nav class="document-nav" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">Contents</span>
                        </a>
                        
                        <a href="topic-02-antihypertensives.html" class="nav-button nav-button--prev" aria-label="Previous section">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Antihypertensives</span>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span class="progress-current">03</span>
                                <span class="progress-separator">/</span>
                                <span class="progress-total">06</span>
                            </div>
                            <div class="progress-bar-container" aria-hidden="true">
                                <div class="progress-bar-fill" style="width: 50%;"></div>
                            </div>
                            <span class="progress-label">Heart Failure Management</span>
                        </div>
                        
                        <a href="topic-04-ischemic-heart-disease.html" class="nav-button nav-button--next" aria-label="Next section">
                            <span class="nav-text">Ischemic Heart Disease</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>

                <!-- Breadcrumb -->
                <nav class="breadcrumb" aria-label="Breadcrumb">
                    <ol class="breadcrumb-list">
                        <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                        <li class="breadcrumb-item"><a href="../index.html">Cardiovascular System</a></li>
                        <li class="breadcrumb-item active" aria-current="page">Drugs used in Heart Failure</li>
                    </ol>
                </nav>

                <!-- Document Header -->
                <header class="document-header">
                    <div class="header-badge">
                        <span class="badge-icon">üìñ</span>
                        <span class="badge-text">Lecture Notes</span>
                    </div>
                    <h1 class="document-title">Drugs used in Heart Failure</h1>
                    <div class="title-meta">
                        <span class="meta-item">
                            <span class="meta-icon">üë§</span>
                            <span>By Geoffrey M.</span>
                        </span>
                        <span class="meta-item">
                            <span class="meta-icon">üìÖ</span>
                            <span>30th October 2023</span>
                        </span>
                    </div>
                </header>

                <!-- Main Content Area -->
                <div class="content-wrapper">
                    
                    <!-- START: learning-objectives -->
                    <section id="learning-objectives" class="content-section">
                        <div class="section-header">
                            <h2 class="section-title">
                                <span class="title-icon">üéØ</span>
                                Learning objectives
                            </h2>
                        </div>
                        <div class="content-card">
                            <p>By the end of the lesson the student should be able to;</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Explain the pathophysiology of heart failure and the cardinal features</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Describe the classes of drugs used in heart failure, their mechanism of actions and their adverse effects.</span>
                                </li>
                            </ol>
                        </div>
                    </section>
                    <!-- END: learning-objectives -->

                    <!-- START: introduction -->
                    <section id="introduction" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üè•</span>
                                Introduction
                            </h2>
                        </div>
                        <div class="content-card">
                            <p>Heart failure is a progressive disorder in which the heart is unable to pump sufficient blood to meet the needs of the body.</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Common causes of heart failure are artery coronary disease and hypertension. Others are; myocardial infarction, congenital heart anomalies, valvular heart diseases, and dilated cardiomyopathy.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">In heart failure, the heart is impaired to fill or eject blood.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The impairment of the ability of the heart to pump blood depends on the side of the heart affected.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Right heart failure causes blood accumulation in the venous circulation leading to organ congestion and peripheral edema.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Other classifications of heart failure are;</span>
                                    <ol class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Systolic heart failure with reduced contractility and reduce ejection fraction.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Diastolic heart failure with stiffening and reduced relaxation.</span></li>
                                    </ol>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Left heart failures causes accumulation of blood in the pulmonary circulation and fluid in the lung.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">A reduced cardiac output, causes reduced blood flow to the organs hence decreased blood flow to the kidneys, urine production is decreased culminating to fluid retention and more peripheral edema.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">To compensate for reduced cardiac out put, the sympathetic nervous activity is elevated and renin-angiotensin aldosterone system (RAAS) is activated.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">SNS stimulates the adrenal medulla to release noradrenaline and adrenaline which increases the heart rate and peripheral vasoconstriction.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">RAAS is activated to correct poor perfusion of the kidneys. However, aldosterone released causes salt and water retention causing further congestion and edema.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Increased stretch of chamber walls leads to release of natriuretic factors; atrial natriuretic factor (atrial wall) and brain natriuretic factor (ventricular wall).</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">These/peptides decrease blood volume and blood pressure through; water and sodium excretion, and vasodilation of arterioles and venules.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">At long run these compensatory mechanisms do harm than good. i.e the vasoconstriction increases the workload of the heart (afterload)&gt;myocardial damage &gt; more heart failure.</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: introduction -->

                    <!-- START: pathophysiology -->
                    <section id="pathophysiology" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü©∫</span>
                                Pathophysiology of HF
                            </h2>
                        </div>
                        <div class="content-card">
                            <p>Heart failure is a syndrome with many causes.
                            Diastolic dysfunction occurs due to stiffening and myocardial hypertrophy.
                            High output failure is common in hyperthyroidism, beriberi, anaemia and arteriovenous shunts.</p>

                            <p>Systolic dysfunction causes reduced cardiac output and reduce ejection fraction.</p>

                            <p>Decreased exercise tolerance and fatigue is consequence of reduced cardiac output.</p>

                            <p>Compensatory mechanisms occurs through sympathetic nervous system and renin-angiotensin-aldosterone response.</p>

                            <p>Increased sympathetic output leads to tachycardia, increased contractility and vascular tone.</p>
                        </div>
                    </section>
                    <!-- END: pathophysiology -->

                    <!-- START: signs-symptoms -->
                    <section id="signs-symptoms" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö†Ô∏è</span>
                                Signs and Symptoms of HF
                            </h2>
                        </div>
                        <div class="content-card">
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Shortness of breath</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Orthopnoea</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dyspnoea</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Swelling of lower limbs</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tachycardia</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Cardiomegaly</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increased jugular venous pressure</span></li>
                            </ol>
                        </div>
                    </section>
                    <!-- END: signs-symptoms -->

                    <!-- START: classifications-goals -->
                    <section id="classifications-goals" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìä</span>
                                Classifications & Goals
                            </h2>
                        </div>
                        <div class="content-card">
                            <h3>10 New York HF Classification</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Class I- the patient is asymptomatic, no limitation to daily activities</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Class II- Slight limitation of physical activity (Mild HF); features of fatigue, dyspnea, palpitations or angina pectoris.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Class III- Marked limitation of physical activity; ordinary activity causes symptoms (moderate HF)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Class IV- symptomatic at rest; unable to carry any physical activity without discomfort (severe HF).</span></li>
                            </ol>

                            <h3>10 Goals in heart failure treatment</h3>
                            <p>1.To Reduce the symptoms and slow HF progression.
                            2.Managing acute episodes of decompensated heart failure.
                            3. Decrease mortality and improve quality of life and survival .
                            4.To treat the cause if it can resolve.</p>

                            <h3>12 Goals for pharmacological Intervention</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reducing myocardial work load</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decrease extracellular fluid volume</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Improve cardiac contractility</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce the rate of cardiac remodeling</span></li>
                            </ol>

                            <h3>Strategy of Treatment</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce the afterload (forward failure).</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce the preload (backward failure).</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Improve contractility of the heart.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce fluid intake $ &lt; 1.5 - 2 \text{ L/} $ day</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce salt intake</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Treat comorbidities</span></li>
                            </ol>
                            <p>Judicious use of diuretics and ACE-inhibitors
                            8. Use of inotropic agents only in acute HF</p>

                            <h3>14 Classification of Drugs</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Diuretics</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Beta blockers</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Vasodilators</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Angiotensin converting enzyme inhibitors/angiotensin receptor blockers</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Cardiac glycosides (inotropic agents)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Brain natriuretic peptide</span></li>
                            </ol>
                            <p>Vasopressin receptor antagonist (aldosterone antagonist)</p>
                        </div>
                    </section>
                    <!-- END: classifications-goals -->

                    <!-- START: cardiac-glycosides -->
                    <section id="cardiac-glycosides" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ù§Ô∏è</span>
                                Digitalis/Cardiac glycoside
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Cardiac glycosides e.g. digoxin, digitoxin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Digoxin is obtained from digitalis lanata the foxglove white.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Used as second line therapy owing to their toxicity.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They act by influencing the movement of ions in and out of the myocardial fibers and alter activity of autonomic nervous system.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The ions most affected is sodium and calcium.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They have both positive inotropy and negative chronotropy.</span></li>
                            </ul>

                            <h3>Mode of Action of Digitalis</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increase contraction of cardiac sarcomeres leading to increased free ca2+ hence increased cardiac contraction.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Slow the rate and rhythm through slowing AV node conduction via vagal stimulation</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increase force and contraction of the heart through inhibition of $\text{Na}^+/\text{K}^+$ ATpase pump, and increase $\text{Ca}^{2+}$ stores.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Can affect other organs with smooth muscles like git, CNS,</span></li>
                            </ol>

                            <aside class="callout callout--note" role="note">
                                <div class="callout-content">
                                    <p><strong>The cardiac glycosides affect the movement of ions across the myocardial cell membrane and intracellular electrolyte levels (particularly sodium, potassium, and calcium) in four ways. 1 They inhibit the enzyme Na‚Å∫/K‚Å∫-ATPase, which powers the sodium‚Äìpotassium pump. 2 They affect sodium‚Äìcalcium exchange across the membrane. The net result of these effects is that sodium accumulates within the myocardial cell. The cardiac glycosides also elevate intracellular calcium levels by 3 openings membrane calcium channels, and 4 triggering the release of calcium ions from intracellular storage sites. The net result of the latter effects is that the force of myocardial contraction is enhanced.</strong></p>
                                </div>
                            </aside>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251214-b69f39aa.jpeg" 
                                         alt="Diagram of cardiac glycoside mechanism of action" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Mechanism of Action of Cardiac Glycosides</figcaption>
                            </figure>

                            <h3>Pharmacokinetics</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Absorption is $ 65-80 \% $ after oral administration</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Not fully metabolized in the human body</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">A third excreted unchanged in the urine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Half life is 36-40 hours.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They have narrow therapeutic index with only small difference between therapeutic dose and doses that are toxic</span></li>
                            </ul>

                            <h3>Pharmacodynamics</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibit Na+/K+ Atpase pump (sodium pump)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibition of sodium pump leads to <strong>positive inotropy</strong>.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increase heart muscle contraction by slowing conduction velocity through <strong>AV</strong> node. This is useful in atrial fibrillation</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Neurohormonal inhibition‚Äîmechanism of action not well known. Low dose inhibit sympathetic activation with minimal effects on contractility. Used in HF with reduced injection fraction (ref)</span></li>
                            </ul>

                            <h3>Adverse Effects of Glycosides</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Nausea, vomiting and diarrhea</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dysrhythmias</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Block of AV conduction</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increased Ectopic pacemaker activity.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">CNS-hallucinations and visual disturbance</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Cardiac glycosides and potassium compete for the binding enzyme Atpase. Therefore, high levels of potassium reduce the effects of glycoside while low levels of potassium enhance the effects of these drugs.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Gynaecomastia</span></li>
                            </ol>
                            <p>Bigeminal rhythm (ectopic heart beat following a normal heart beat)
                            9. Incase of digitalis toxicity, Digibind (digoxin antibody) is given as an antidote.</p>
                        </div>
                    </section>
                    <!-- END: cardiac-glycosides -->

                    <!-- START: other-hf-drugs -->
                    <section id="other-hf-drugs" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Other Pharmacological Agents
                            </h2>
                        </div>
                        <div class="content-card">
                            <h3>Diuretics</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Act by increasing water and salt loss hence reducing the preload volume.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduced preload leads to improved cardiac function, reduction of peripheral oedema and decreased dyspnoea.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Loop diuretics can be given orally e.g. furosemide, bumetanide</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Severe cases of HF give parenteral loop diuretics</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Aldosterone antagonist can be added to loop diuretics to counter $\text{K}^+$ loss and improve efficiency of loop diuretics.</span></li>
                            </ul>

                            <h3>Vasodilators</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Mixed arteriolar and venodilators reduce both afterload and preload e.g. sodium nitroprusside, calcium channel antagonist</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Venodilatory predominance reduce preload;- nitrates</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Arteriolar predominance reduce after load;- hydralazine, minoxidil</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Vasodilators like <em>hydralazine</em> dilate arterioles leading to increased cardiac output.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Nitr√≥glycerin and sodium nitroprusside</strong> are given i.v in severe heart failure.</span></li>
                            </ul>

                            <h3>ACE-Inhibitors</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They are the mainstay of treatment in heart failure.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Standard for treatment all types of HF</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibit conversion of angiotensin I to angiotensin II which is a potent vasoconstrictor.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They have shown to reduce the disease progression, improve quality of life and boost survival rate of people with NYHA class II, III and IV.</span></li>
                            </ul>

                            <h3>25 ACE-Inhibitors</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decrease vascular resistance leading to increased stroke volume and improved tissue perfusion</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decrease aldosterone production leading to sodium and water loss reducing the preload volume.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reverse ventricular hypertrophy and remodeling by reducing AII and aldosterone levels</span></li>
                            </ul>

                            <p>ACEIs reduce mortality, hospitalization and slow disease progression.
                            ARBS competitively block AT1 receptors on the heart, peripheral vasculature and kidney leading to similar actions of ACEIs.</p>
                            <p>ARBS are given to patients who can not tolerate the cough effect of ACEIs.</p>

                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../assets/images/image-20251214-2172f303.jpeg" 
                                         alt="Figure 50.3 The effects of angiotensin-converting enzyme inhibitors" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Figure 50.3 The effects of angiotensin-converting enzyme inhibitors</figcaption>
                            </figure>

                            <h3>Beta-Adrenergic Blockers</h3>
                            <p>Nebivolol, carvedilol, metoprolol and bisoprolol block the effects of catecholamines on the heart.</p>
                            <p>Improve left ventricular structure and function.
                            Decrease wall stress and improve ejection fraction.
                            Decrease frequency of arrhythmias
                            Improve patient progress and reduce hospitalization.</p>

                            <h3>29 Aldosterone Antagonist</h3>
                            <p>Spironolactone and eplerenone block actions of aldosterone
                            Reduce preload volume
                            Prevent effects of aldosterone like remodeling and ventricular hypertrophy
                            They are potassium sparing
                            Used in conjunction with other drugs in severe heart failure</p>

                            <h3>Natriuretic peptides</h3>
                            <p>Nesiritide in combination with brain natriuretic peptide(BNP) are used in acute compensated heart failure.</p>
                            <p>Vasodilator and administered intravenously, hypotension being common.</p>

                            <h3>Bipyridines</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inamrinone and milrinone inhibit phosphodiesterase enzyme-3 (PDE-3)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Increase contractility through calcium influx in heart during action potential.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Also have vasodilating effects</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effects;- nausea, and vomiting, arrhythmias, liver enzyme changes and thrombocytopenia.</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: other-hf-drugs -->

                    <!-- START: summary-revision -->
                    <section id="summary-revision" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìù</span>
                                Summary & Revision
                            </h2>
                        </div>
                        <div class="content-card">
                            <h3>Summary</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Stage A- high risk with no symptoms.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce risk factors, treat hypertension, diabetes, dyslipidemia, ACE inhibitors or ARBs in some patients</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Stage B- structural heart disease with no symptoms.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">ACE inhibitors, $\beta$-blockers in some selected patients</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Stage C- structural heart disease and obvious symptoms or current symptoms</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">ACE inhibitors, $\beta$-blockers in all patients, aldosterone antagonist, sodium restriction, digoxin and diuretics.</span></li>
                            </ul>

                            <h3>Revision</h3>
                            
                            <div class="collapsible-section">
                                <details class="collapsible-section">
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ùì</span>
                                        <span class="trigger-text">1. Which electrolyte is important to monitor in a patient taking digoxin?</span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>A. Chloride</p>
                                        <p>B. Sodium</p>
                                        <p>C. Potassium</p>
                                        <p>D. Zinc</p>
                                        <hr>
                                        <h4>Answer</h4>
                                        <ul class="enhanced-list">
                                            <li class="list-item"><span class="list-marker"></span><span class="list-content">The answer is C. hypokalemia can lead to life-threatening arrhythmias and increases the potential of cardiac toxicity with digoxin.</span></li>
                                            <li class="list-item"><span class="list-marker"></span><span class="list-content">Because of reduced competition at the $\text{K}^+$ binding site on the $\text{N}^+/\text{K}^+$ ATpase.</span></li>
                                        </ul>
                                    </div>
                                </details>
                            </div>

                            <div class="collapsible-section">
                                <details class="collapsible-section">
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ùì</span>
                                        <span class="trigger-text">2. Which best describes the action of ACE inhibitors in heart failure?</span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>A. ACE inhibitors increase vascular resistance</p>
                                        <p>B. ACE inhibitors decrease cardiac output</p>
                                        <p>C. ACE inhibitors reduce the preload</p>
                                        <p>D. ACE inhibitors increase aldosterone</p>
                                        <hr>
                                        <h4>Answer</h4>
                                        <ul class="enhanced-list">
                                            <li class="list-item"><span class="list-marker"></span><span class="list-content">The answer is C. ACE inhibitors decrease vascular resistance leading to decreased preload, decreased afterload, and increase cardiac output.</span></li>
                                            <li class="list-item"><span class="list-marker"></span><span class="list-content">ACE inhibitors blunt/block aldosterone release.</span></li>
                                        </ul>
                                    </div>
                                </details>
                            </div>
                        </div>
                    </section>
                    <!-- END: summary-revision -->

                </div>

                <!-- Bottom Navigation -->
                <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="topic-02-antihypertensives.html" class="nav-button nav-button--prev nav-button--large">
                            <span class="nav-icon">‚Üê</span>
                            <div class="nav-content">
                                <span class="nav-label">Previous</span>
                                <span class="nav-title">Antihypertensives</span>
                            </div>
                        </a>
                        
                        <a href="../index.html" class="nav-button nav-button--toc">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">All Topics</span>
                        </a>
                        
                        <a href="topic-04-ischemic-heart-disease.html" class="nav-button nav-button--next nav-button--large">
                            <div class="nav-content">
                                <span class="nav-label">Next</span>
                                <span class="nav-title">Ischemic Heart Disease</span>
                            </div>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>